Aptevo Therapeutics Inc.
Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapy candidates for cancer. Its wholly owned ADAPTIR and ADAPTIR-FLEX protein technology platforms support the design of monospecific, bispecific and multi-specific immunotherapeutic proteins. The pipeline includes clinical candidates mipletamig, a CD123-by-CD3 T cell engager being evaluated for acute myeloid leukemia, and ALG.APV-527, which targets 4-1BB and the 5T4 tumor antigen in solid tumors, as well as six preclinical candidates. Aptevo develops drug candidates using its platforms and conducts preclinical and clinical development. It also collaborates with Alligator Bioscience AB on ALG.APV-527; the partners intend to share revenue from a third-party commercialization partner under the terms of their agreement. Aptevo is headquartered in Seattle, Washington.
No SEC Form 4 filings for $APVO in the last 30 days.
See all $APVO insider activity →Aptevo Therapeutics (APVO) raised $3M via warrant exercises at $1.08/share. New warrants for 13.89M shares at the same price were issued, potentially adding $15M if exercised. Proceeds will fund working capital and corporate purposes, per an SEC filing.
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds SEATTLE, WASHINGTON - November 11, 2026 - Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company developing novel multispec
Aptevo Therapeutics presented preclinical data at SITC 2026 for APVO451, APVO452, and APVO711, showing potential in treating solid tumors by activating immune cells. APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation, while APVO711 combined CD40 activation with PD-L1 blockade. The company plans to continue developing these treatments.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning APVO (Aptevo Therapeutics Inc.). Coverage has skewed bullish: 2 bullish, 6 neutral, and 1 bearish.
Recent APVO coverage spans corporate actions, technology and financial news.
The capital raise provides working‑capital but dilutes existing shareholders.
A modest cash infusion dilutes existing shareholders but provides working‑capital.
Positive preclinical results could boost investor optimism and drive short‑term upside.
Preclinical data suggest the molecules can kill tumor cells under immunosuppressive conditions, potentially de‑risking later clinical programs.
The tolerability improvement removes a major risk factor, likely enhancing investor sentiment and supporting a price rise.
AlphAI scores every news story that mentions APVO with an AI model for sentiment and relevance, and aggregates insider trades from Aptevo Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aptevo Therapeutics (APVO) raised $3M via warrant exercises at $1.08/share. New warrants for 13.89M shares at the same price were issued, potentially adding $15M if exercised. Proceeds will fund working capital and corporate purposes, per an SEC filing.
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds SEATTLE, WASHINGTON - November 11, 2026 - Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company developing novel multispec
Aptevo Therapeutics presented preclinical data at SITC 2026 for APVO451, APVO452, and APVO711, showing potential in treating solid tumors by activating immune cells. APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation, while APVO711 combined CD40 activation with PD-L1 blockade. The company plans to continue developing these treatments.
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity—offering potential for difficult-
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further streng
Aptevo Therapeutics (APVO) reported fewer infusion reactions with mipletamig after refining its priming-dose regimen. The RAINIER study is expected to complete by year-end 2026, with Phase 2 development planned for 2027.
Aptevo Therapeutics (APVO) will report Q3'26 earnings on November 5. Analysts expect $0 revenue and a loss of $3.71 per share. Details available on the company's financials page.
Aptevo Therapeutics filed a prospectus supplement for a $2.31M ATM offering of common stock. As of October 30, it had sold 303,157 shares for $11.8M in gross proceeds. The offering is under an agreement with Roth Capital Partners and is registered under Form S-3.
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Filing of Prospectus Supplement On October 30, 2026, Aptevo Therapeutics Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as
Aptevo Therapeutics (APVO) will report Q3'26 earnings on November 5. Analysts expect 0 USD revenue and a loss of 3.71 USD per share, according to the company.
